Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study
暂无分享,去创建一个
M. Dimopoulos | N. Pavlidis | G. Fountzilas | A. Bamias | D. Skarlos | T. Makatsoris | I. Varthalitis | P. Papakostas | E. Samantas | N. Xiros | G. Aravantinos | E. Briasoulis | N. Mylonakis | H. Kalofonos